Abstract
Immunotherapy emerges as a treatment strategy for breast cancer marker, diagnosis and treatment. In this review, monoclonal antibodies (mAbs)-based passive and peptide vaccines as active immunotherapy approaches like activation of B-cells and T-cells are studied. Passive immunotherapy is mAbs-based therapy effective against tumor cells, which acts by targeting HER2, IGF 1R, VEGF, BCSC and immune checkpoints. Neuropeptide Y (NPY) and GPCR are the areas of interest to target BC metastases for on-targeting therapeutic action. Neuropeptide S (NPS) or NPS receptor 1, acts as a biomarker for Neuroendocrine tumors (NET), mostly characterized by synaptophysin and chromogranin-A expression or Ki-67 proliferation index. The protein fusion technologies arise as a promising avenue in plant expression systems for increased recombinant Ab accumulation and cost-efficient purification. Recently, mAbs-based immunotherapy effectiveness is appreciated as a novel therapeutic combination of chemotherapy and immunotherapy to reduce the side effects and improve therapeutic responsiveness. Synthetic drug resistance will be overcome by mAbs-based therapy through several clinical trials and detection methods need to be optimized for accuracy and precision. Pharmacokinetic attributes need to be accessed for preferred receptor-agonist activity without ligand accumulation.
Keywords: Antigen, receptor, immunity, immunotherapy, antibody, breast cancer.
Graphical Abstract
[http://dx.doi.org/10.3892/ol.2014.2721] [PMID: 25624911]
[http://dx.doi.org/10.2967/jnumed.114.142000] [PMID: 25189338]
[http://dx.doi.org/10.1007/5584_2019_427] [PMID: 31468359]
[http://dx.doi.org/10.1016/j.preteyeres.2015.03.001] [PMID: 25797468]
[http://dx.doi.org/10.1111/apha.12445] [PMID: 25545642]
[http://dx.doi.org/10.1016/j.npep.2015.09.008] [PMID: 26441327]
[http://dx.doi.org/10.1093/rb/rbv013] [PMID: 26816643]
[PMID: 11389101]
[http://dx.doi.org/10.2174/156802607782341019] [PMID: 17979777]
[http://dx.doi.org/10.1007/s000180300029] [PMID: 12678499]
[http://dx.doi.org/10.1016/S0167-0115(01)00388-3] [PMID: 11853873]
[http://dx.doi.org/10.1371/journal.pone.0051032] [PMID: 23236424]
[http://dx.doi.org/10.1158/0008-5472.CAN-05-2744] [PMID: 16585197]
[http://dx.doi.org/10.1016/j.pharmthera.2011.03.011] [PMID: 21439311]
[http://dx.doi.org/10.1158/1541-7786.MCR-09-0301] [PMID: 20332211]
[http://dx.doi.org/10.1159/000486225] [PMID: 29310113]
[http://dx.doi.org/10.1016/j.npep.2015.10.005] [PMID: 26549645]
[http://dx.doi.org/10.1021/jm001065f] [PMID: 11311056]
[http://dx.doi.org/10.1186/s12906-017-1638-y] [PMID: 28231775]
[http://dx.doi.org/10.1155/2015/306164] [PMID: 26550566]
[http://dx.doi.org/10.1634/theoncologist.12-9-1084] [PMID: 17914078]
[http://dx.doi.org/10.2165/00003495-200666120-00004] [PMID: 16956305]
[http://dx.doi.org/10.1586/1744666X.2014.916211] [PMID: 24867051]
[PMID: 29061772]
[http://dx.doi.org/10.3390/pharmaceutics10030083] [PMID: 29973504]
[http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.2018020229] [PMID: 30317946]
[http://dx.doi.org/10.1089/hyb.1996.15.159] [PMID: 8743297]
[http://dx.doi.org/10.1158/0008-5472.CAN-04-2192] [PMID: 15753367]
[PMID: 10537299]
[http://dx.doi.org/10.1002/ijc.26350] [PMID: 21823118]
[http://dx.doi.org/10.1007/s00428-014-1602-x] [PMID: 24915894]
[http://dx.doi.org/10.1016/j.peptides.2006.08.037] [PMID: 17223228]